Switch theme
Sign up to access all valuation multiples
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
1987
952
LTM Revenue $804M
LTM EBITDA $52.2M
$686M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Novavax has a last 12-month revenue (LTM) of $804M and a last 12-month EBITDA of $52.2M.
In the most recent fiscal year, Novavax achieved revenue of $682M and an EBITDA of -$108M.
Novavax expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Novavax valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $804M | XXX | $682M | XXX | XXX | XXX |
| Gross Profit | $643M | XXX | $479M | XXX | XXX | XXX |
| Gross Margin | 80% | XXX | 70% | XXX | XXX | XXX |
| EBITDA | $52.2M | XXX | -$108M | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | -16% | XXX | XXX | XXX |
| EBIT | $13.1M | XXX | -$249M | XXX | XXX | XXX |
| EBIT Margin | 2% | XXX | -36% | XXX | XXX | XXX |
| Net Profit | $37.8M | XXX | -$187M | XXX | XXX | XXX |
| Net Margin | 5% | XXX | -27% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Novavax's stock price is $7.
Novavax has current market cap of $1.2B, and EV of $686M.
See Novavax trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $686M | $1.2B | XXX | XXX | XXX | XXX | $0.14 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Novavax has market cap of $1.2B and EV of $686M.
Novavax's trades at 1.0x EV/Revenue multiple, and -6.3x EV/EBITDA.
Equity research analysts estimate Novavax's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Novavax has a P/E ratio of 31.5x.
See valuation multiples for Novavax and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV (current) | $686M | XXX | $686M | XXX | XXX | XXX |
| EV/Revenue | 0.9x | XXX | 1.0x | XXX | XXX | XXX |
| EV/EBITDA | 13.1x | XXX | -6.3x | XXX | XXX | XXX |
| EV/EBIT | 52.4x | XXX | -2.8x | XXX | XXX | XXX |
| EV/Gross Profit | 1.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 31.5x | XXX | -6.3x | XXX | XXX | XXX |
| EV/FCF | 44.2x | XXX | -6.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNovavax's last 12 month revenue growth is -2%
Novavax's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.8M for the same period.
Novavax's rule of 40 is -89% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Novavax's rule of X is 2% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Novavax and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -2% | XXX | -12% | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | -16% | XXX | XXX | XXX |
| EBITDA Growth | 432% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -89% | XXX | -18% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 2% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 57% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 107% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Novavax acquired XXX companies to date.
Last acquisition by Novavax was XXXXXXXX, XXXXX XXXXX XXXXXX . Novavax acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Novavax founded? | Novavax was founded in 1987. |
| Where is Novavax headquartered? | Novavax is headquartered in United States of America. |
| How many employees does Novavax have? | As of today, Novavax has 952 employees. |
| Who is the CEO of Novavax? | Novavax's CEO is Mr. John C. Jacobs. |
| Is Novavax publicy listed? | Yes, Novavax is a public company listed on NAS. |
| What is the stock symbol of Novavax? | Novavax trades under NVAX ticker. |
| When did Novavax go public? | Novavax went public in 1995. |
| Who are competitors of Novavax? | Similar companies to Novavax include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Novavax? | Novavax's current market cap is $1.2B |
| What is the current revenue of Novavax? | Novavax's last 12 months revenue is $804M. |
| What is the current revenue growth of Novavax? | Novavax revenue growth (NTM/LTM) is -2%. |
| What is the current EV/Revenue multiple of Novavax? | Current revenue multiple of Novavax is 0.9x. |
| Is Novavax profitable? | Yes, Novavax is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Novavax? | Novavax's last 12 months EBITDA is $52.2M. |
| What is Novavax's EBITDA margin? | Novavax's last 12 months EBITDA margin is 6%. |
| What is the current EV/EBITDA multiple of Novavax? | Current EBITDA multiple of Novavax is 13.1x. |
| What is the current FCF of Novavax? | Novavax's last 12 months FCF is $15.5M. |
| What is Novavax's FCF margin? | Novavax's last 12 months FCF margin is 2%. |
| What is the current EV/FCF multiple of Novavax? | Current FCF multiple of Novavax is 44.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
